PUBLISHER: TechNavio | PRODUCT CODE: 1267560
PUBLISHER: TechNavio | PRODUCT CODE: 1267560
Technavio has been monitoring the diabetes management devices market and is forecast to grow by USD 10.9 bn during 2022-2027, accelerating at a CAGR of 8.18% during the forecast period. Our report on the diabetes management devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global burden of diabetes, growing demand for advanced insulin delivery devices, and new product launches.
Technavio's diabetes management devices market is segmented as below:
By Product Type
By Distribution Channel
By Geographical Landscape
This study identifies the growing focus on artificial pancreas as one of the prime reasons driving the diabetes management devices market growth during the next few years. Also, increasing focus on home care settings and technological advancements in the healthcare sector will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the diabetes management devices market covers the following areas:
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diabetes management devices market vendors that include Abbott Laboratories, B. Braun Melsungen AG, Bionime Corp., Dexcom Inc., F. Hoffmann La Roche Ltd., iHealth Labs Inc., Insulet Corp., Medtronic Plc, Nemaura Medical Inc., Nipro Corp., Nova Biomedical Corp., Novo Nordisk AS, PHC Holdings Corp., Prodigy Diabetes Care LL, Sanofi SA, Senseonics Holdings Inc., WellDoc Inc., Tandem Diabetes Care Inc., LifeScan IP Holdings LLC, and Eli Lilly and Co.. Also, the diabetes management devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Exhibits: